Disease · MONDO_0005036

gastric adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric adenocarcinoma. Diseases, record MONDO_0005036. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005036

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005036; Open Targets
Other names: adenocarcinoma - stomach, adenocarcinoma of stomach, adenocarcinoma of the stomach, gastric (stomach) adenocarcinoma, stomach adenocarcinoma; Open Targets
Disease Ontology: DOID:3717; Disease Ontology
NCI Thesaurus: C4004; NCI Thesaurus
Orphanet: ORPHA:464463; Orphanet
Highest stage of its drugs: Approval, for 4 of its 236 drugs, from ClinicalTrials.gov, FDA and TTD; Open Targets

Drugs236

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Approval	ClinicalTrials.gov	95	93	87	Drugs and targets
RAMUCIRUMAB	CHEMBL1743062	Antibody	Approval	ClinicalTrials.gov and TTD	43	42	42	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Approval	ClinicalTrials.gov, at phase 4	36	33	32	Drugs and targets
ZOLBETUXIMAB	CHEMBL2109427	Antibody	Approval	FDA	15	12	12	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	236	236	222	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	148	148	145	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	120	120	113	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	81	81	80	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	66	66	66	Drugs and targets
S1?	CHEMBL4525128		Phase 3	ClinicalTrials.gov and TTD	57	56	6	Drugs and targets

1 to 10 of 236

See all 236 drugs

Targets205

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	15	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
ERBB2	ErbB-2/ErbB-3 heterodimer	13	ErbB-2/ErbB-3 heterodimer inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
EGFR	Epidermal growth factor receptor	11	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	11	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	11	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	11	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	11	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	11	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 205

See all 205 targets

Trials597

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03675737	Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)	Phase 3	1,579	2023-10-12	Stomach Neoplasms	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03221426	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)	Phase 3	1,007	2025-02-20	Gastric Cancer, Gastroesophageal Junction Cancer	CAPECITABINE, CISPLATIN, DOCETAXEL, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03777657	Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma	Phase 3	997	2025-02-14	Gastric, or Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01457846	Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer	Phase 2	960	2017-03-07	Gastro-oesophageal Junction Cancer, Gastric Cancer	FEXAGRATINIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00678535	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Phase 3	904	2013-05-16	Gastric Cancer	CAPECITABINE, CETUXIMAB, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00296335	Trial of Adjuvant Chemotherapy for Gastric Cancer	Phase 3	855	2014-02-27	Stomach Cancer	CISPLATIN, DOXIFLURIDINE, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	Phase 3	763	2020-03-13	Gastric Adenocarcinoma	CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02178956	A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Phase 3	714	2021-05-10	Gastric Cancer, Gastroesophageal Junction Cancer	NAPABUCASIN	Its record names the disease	ClinicalTrials.gov
NCT01170663	A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma	Phase 3	665	2014-07-31	Gastric Cancer	PACLITAXEL, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT02314117	A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Phase 3	645	2018-05-02	Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 597

See all 597 trials

Comparisons in its trials94

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)	267 of 785	206 of 787	1,572	NCT03675737	Trial comparisons
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE)	776 of 785	771 of 787	1,572	NCT03675737	Trial comparisons
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: deaths from any cause	397 of 501	431 of 496	997	NCT03777657	Trial comparisons
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: serious adverse events	211 of 498	179 of 494	992	NCT03777657	Trial comparisons
Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: Safety - Number of Participants With Adverse Events (AEs)	446 of 446	432 of 436	882	NCT00678535	Trial comparisons
Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin: serious adverse events	239 of 446	194 of 436	882	NCT00678535	Trial comparisons
Mitomycin Plus Short-term Fluoropyrimidine vs Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati: serious adverse events	3 of 422	5 of 425	847	NCT00296335	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: Number of Patients With Adverse Events	352 of 357	338 of 350	707	NCT02178956	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause	286 of 357	275 of 350	707	NCT02178956	Trial comparisons
Napabucasin + Paclitaxel vs Placebo + Paclitaxel: serious adverse events	125 of 357	101 of 350	707	NCT02178956	Trial comparisons

1 to 10 of 94

See all 94 comparisons in its trials

Papers from its trials314

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41653501	RESULT	1	PubMed
41324998	RESULT	2	PubMed
41202501	RESULT	1	PubMed
40025394	RESULT	1	PubMed
39792482	RESULT	1	PubMed
39383487	RESULT	2	PubMed
38134948	RESULT	1	PubMed
37963317	RESULT	2	PubMed
37875143	RESULT	1	PubMed
36603169	RESULT	1	PubMed

1 to 10 of 314

See all 314 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005036

GET https://conductscience.org/api/diseases/v1/MONDO_0005036/drugs?page=2

API reference For AI assistants